全文获取类型
收费全文 | 724篇 |
免费 | 33篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 8篇 |
妇产科学 | 42篇 |
基础医学 | 37篇 |
口腔科学 | 100篇 |
临床医学 | 23篇 |
内科学 | 231篇 |
皮肤病学 | 14篇 |
神经病学 | 23篇 |
特种医学 | 18篇 |
外科学 | 130篇 |
综合类 | 3篇 |
预防医学 | 10篇 |
眼科学 | 2篇 |
药学 | 21篇 |
肿瘤学 | 93篇 |
出版年
2023年 | 5篇 |
2022年 | 7篇 |
2021年 | 31篇 |
2020年 | 8篇 |
2019年 | 13篇 |
2018年 | 32篇 |
2017年 | 17篇 |
2016年 | 22篇 |
2015年 | 20篇 |
2014年 | 28篇 |
2013年 | 39篇 |
2012年 | 54篇 |
2011年 | 59篇 |
2010年 | 35篇 |
2009年 | 32篇 |
2008年 | 47篇 |
2007年 | 67篇 |
2006年 | 48篇 |
2005年 | 48篇 |
2004年 | 30篇 |
2003年 | 25篇 |
2002年 | 30篇 |
2001年 | 11篇 |
2000年 | 9篇 |
1999年 | 8篇 |
1998年 | 7篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1990年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 3篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1967年 | 2篇 |
排序方式: 共有761条查询结果,搜索用时 31 毫秒
1.
2.
Fabio Ghezzi Maurizio Serati Antonella Cromi Stefano Uccella Stefano Salvatore Paola Triacca Pierfrancesco Bolis 《International urogynecology journal》2006,17(4):335-339
The purpose of this study was to evaluate the outcome of tension-free vaginal tape (TVT) procedure in women with urodynamic stress incontinence diagnosed as having intrinsic sphincteric deficiency (ISD). The combination of a maximal urethral closure pressure <20 cm H2O and a Valsalva leak point pressure <60 cm H2O was considered as diagnostic of ISD. Subjects with detrusor overactivity on preoperative urodynamics were excluded. A total of 35 patients with both low closure pressure and leak point pressure were enrolled. Bladder perforation occurred in three (8.6%) cases. Postoperative urinary voiding difficulties occurred in nine (25.7%) women. Two patients underwent surgical detension of the tape, with complete resolution of urinary retention and no relapse of incontinence. Women with postoperative voiding dysfunction had a significantly lower detrusorial pressure at the peak flow on preoperative urodynamics compared to those who voided efficiently after TVT. The mean (range) follow-up time was 12.5 months (3–36). The objective cure rate for stress incontinence was 91.4%. Two of the three (66%) patients in whom the TVT procedure failed had a fixed urethra. De novo urge incontinence was found in five (14.3%) patients. 相似文献
3.
Alberto Bacchi-Modena Pierfrancesco Bolis Carlo Campagnoli Fiorenzo De Cicco Michele Meschia Francesco Pansini Roberto Pisati Gabriele Hüls 《Maturitas》1997,27(3):285-292
Objectives: To assess the efficacy and tolerability of a new matrix patch delivering 0.05 mg estradiol per day (Estraderm MX 50) in postmenopausal women with moderate to severe postmenopausal symptoms. Methods: A multicenter, double-blin, randomized, between-patient, placebo controlled trial in 109 postmenopausal women was carried out. Patches were applied twice weekly for 12 weeks. Patients were assessed at 4, 8 and 12 weeks of treatment. The primary efficacy variable was change from baseline in mean number of moderate to severe hot flushes (including night sweats) per 24 h during the last 2 weeks of treatment. Other variables included Kupperman Index, local and systemic tolerability. Plasma concentrations of estradiol (E2), estrone (E1) and estrone sulfate (E1S) were determined before and after treatment. Results: Estraderm MX was significantly superior to placebo (P < 0.001) in reducing mean number of moderate to severe hot flushes (including night sweats) per 24 h after 4, 8 and 12 weeks of treatment. The estimate of treatment group differences after 12 weeks was 4.2 hot flushes (95% confidence interval: 2.6–5.5). Estraderm MX also significantly reduced Kupperman Index at all time points compared to placebo (P < 0.001). Estraderm MX induced increases in mean E2, E1 and E1S plasma levels as expected (E2: baseline 2.7 pg/ml, 12 weeks 38.9 pg/ml; E1: baseline 18.8 pg/ml, 12 weeks 41.6 pg/ml; E1S: baseline 235.6 pg/ml, 12 weeks 765.1 pg/ml). Overall rates of adverse experiences were similar for Estraderm MX and placebo. The number of patients reporting skin irritation was low and similar in both groups. Conclusions: Estraderm MX 50, a new matrix patch, offers an effective and well tolerated dosage form for transdermal delivery of 0.05 mg E2 per day. 相似文献
4.
Fornaro R Terrizzi A Secco GB Canaletti M Baldi E Bonfante P Sticchi C Baccini P Cittadini G Fiorini G Ferraris R 《Il Giornale di chirurgia》1999,20(1-2):20-24
The Authors report a case of renal hemangiopericytoma, whose interest is related to the extreme rarity (24 cases reported until today), its insidious growth, the late in diagnosis, its uncertain clinical-biological evolution, not always predictable. Considering chemotherapy and radiotherapy ineffectiveness, an adequate treatment for such a neoplasm requires the surgical therapy, which must be followed by a careful follow-up. 相似文献
5.
Marco Herling George Z Rassidakis L Jeffrey Medeiros Theodoros P Vassilakopoulos Kay-Oliver Kliche Gianpaolo Nadali Simonetta Viviani Valeria Bonfante Roberto Giardini Marco Chilosi Christos Kittas Alessandro M Gianni Gianni Bonadonna Giovanni Pizzolo Gerassimos A Pangalis Fernando Cabanillas Andreas H Sarris 《Clinical cancer research》2003,9(6):2114-2120
PURPOSE: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. EXPERIMENTAL DESIGN: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. RESULTS: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P < 0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. CONCLUSIONS: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients. 相似文献
6.
S. Viviani E. Camerini V. Bonfante A. Santoro M. Balzarotti M. Fornier L. Devizzi P. Verderio P. Valagussa G. Bonadonna 《British journal of cancer》1998,77(6):992-997
The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin''s disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. Between August 1988 and June 1993 sIL-2R serum levels were measured in 174 untreated patients; in 137 of them evaluation was repeated at the end of treatment and in 132 also during the follow-up. Baseline sIL-2R levels (mean+/-standard error) were significantly higher in patients than in 65 healthy control subjects (1842+/-129 U ml(-1) vs 420+/-10 U ml(-10, P< 0.0001). At the end of treatment 135 out of 137 evaluated patients achieved complete response (CR) and their mean sIL-2R serum levels were significantly lower than those at diagnosis (635+/-19 U ml(-1) vs 1795+/-122 U ml(-1), P=0.0001). After a median follow-up of 5 years, sIL-2R remained low in 114 patients in continuous CR, while they increased in 9 out of 12 patients (75%) who relapsed. However, a temporary increase was also observed in six patients (5%) still in CR. Treatment outcome in terms of freedom from progression was linearly related to sIL-2R levels. Our study confirms that patients with untreated HD have increased baseline levels of sIL-2R compared with healthy subjects and that their pretreatment values may be an indication of disease outcome similar to other conventional prognostic factors, such as number of involved sites, presence of B symptoms and extranodal extent. 相似文献
7.
Pierfrancesco Tassone Paola Neri Renate Burger Rocco Savino Masood Shammas Laurence Catley Klaus Podar Dharminder Chauhan Serena Masciari Antonella Gozzini Pierosandro Tagliaferri Salvatore Venuta Nikhil C Munshi Kenneth C Anderson 《Clinical cancer research》2005,11(11):4251-4258
Interleukin-6 (IL-6) protects multiple myeloma cells against apoptosis induced by glucocorticoids. Here, we investigated whether inhibition of the IL-6 signaling pathway by the IL-6 receptor superantagonist Sant7 enhances the in vivo antitumor effects of dexamethasone on the IL-6-dependent multiple myeloma cell line INA-6. For this purpose, we used a novel murine model of human multiple myeloma in which IL-6-dependent INA-6 multiple myeloma cells were directly injected into human bone marrow implants in severe combined immunodeficient (SCID) mice (SCID-hu). The effect of in vivo drug treatments on multiple myeloma cell growth was monitored by serial determinations of serum levels of soluble IL-6 receptor (shuIL-6R), which is released by INA-6 cells and served as a marker of tumor growth. In SCID-hu mice engrafted with INA-6 cells, treatment with either Sant7 or dexamethasone alone did not induce significant reduction in serum shuIL-6R levels. In contrast, the combination of Sant7 with dexamethasone resulted in a synergistic reduction in serum shuIL-6R levels after 6 consecutive days of treatment. Gene expression profiling of INA-6 cells showed down-regulation of proliferation/maintenance and cell cycle control genes, as well as up-regulation of apoptotic genes in multiple myeloma cells triggered by Sant7 and dexamethasone combination. In vitro colony assays showed inhibition of myeloid and erythroid colonies from normal human CD34(+) progenitors in response to dexamethasone, whereas Sant7 neither inhibited colony growth nor potentiated the inhibitory effect of dexamethasone. Taken together, these results indicate that inhibition of IL-6 signaling by Sant7 significantly potentiates the therapeutic action of dexamethasone against multiple myeloma cells, providing the preclinical rationale for clinical trials of Sant7 in combination with dexamethasone to improve patient outcome in multiple myeloma. 相似文献
8.
9.
10.
Esther M. Wesselink MD Masieh Abawi MD PhD Nynke H. M. Kooistra MD PhD Teus H. Kappen MD PhD Pierfrancesco Agostoni MD PhD Marielle Emmelot-Vonk MD PhD Wietze Pasma PhD Wilton A. van Klei MD PhD Romy C. van Jaarsveld MSc Charlotte S. van Dongen MSc Pieter A. F. M. Doevendans MD PhD Arjen J. C. Slooter MD PhD Pieter R. Stella MD PhD 《Journal of the American Geriatrics Society》2021,69(11):3177-3185